Results 291 to 300 of about 1,192,795 (361)

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG‐055009, a novel thyroid hormone receptor beta (THR‐β) agonist for metabolic dysfunction‐associated steatohepatitis (MASH), in healthy participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract ALG–055009 is an oral thyroid hormone receptor beta (THR‐β) agonist being evaluated for treating metabolic dysfunction–associated steatohepatitis (MASH). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG‐055009 and bioavailability/food effect.
Hakim Charfi, Benedetta Massetto, Megan Fitzgerald, Kha Le, Stanley Wang, Ifong Kan‐Eng, Meenakshi Venkatraman, Naqvi Mohammad, Lawrence Blatt, Tse‐I Lin, Sushmita M. Chanda, John Fry   +11 more
wiley   +1 more source

Adaptogenic Effects of Mushroom Blend Supplementation on Stress, Fatigue, and Sleep: A Randomised, Double-Blind, and Placebo-Controlled Trial. [PDF]

Brain Behav
Hisamuddin AS, Ramli F, Leo TK, Zain MSC, Wong MS, Suhaili MR, Lee LJ, Lee TY.   +7 more
europepmc   +1 more source

The Pathway to Proof‐of‐Concept for BNC210, a Negative Allosteric Modulator of the Alpha‐7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric Disease

Clinical Pharmacology in Drug Development, EarlyView.
Abstract BNC210 is an investigational small molecule selective negative allosteric modulator of the alpha‐7 nicotinic acetylcholine receptor (α7 nAChR). It is an anxiolytic compound with a novel mechanism of action. In a series of Phase 1 clinical trials in healthy volunteers, psychometric test batteries showed that BNC210 did not cause attention ...
Paul Rolan, Elizabeth Doolin, Dharam Paul, Julia Crossman, Michael Odontiadis, Philippe Danjou, Mark Smith, Spyros Papapetropoulos   +7 more
wiley   +1 more source

Molecular hydrogen inhalation modulates resting metabolism in healthy females: findings from a randomized, double-blind, placebo-controlled crossover study

Pavel Grepl, Michal Botek, Jakub Krejčí, Andrew J. McKune   +3 more
openalex   +1 more source

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram, Michelle Quinlan, Amarnath Bandaru, Suleyman Eralp Bellibas, Asmae Mirkou, Shruti Kapoor, Shefali Kakar   +9 more
wiley   +1 more source

Correction: Dhillon et al. Molecular Insights and Therapeutic Advances in Low-Risk Myelodysplastic Neoplasms: A Clinical Review. <i>Cancers</i> 2025, <i>17</i>, 3610. [PDF]

Cancers (Basel)
Dhillon V, Maciejewski J, Balasubramanian SK.   +2 more
europepmc   +1 more source

Macular Pigment Carotenoid Supplementation for the Preservation of Visual Structure and Function Following a Collegiate Rugby Season. [PDF]

Eye Brain
Kelly J, Papa L, Stringham JM, Griffith O, Slobounov S.   +4 more
europepmc   +1 more source

An updated cost-effectiveness analysis of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer: the perspective of the United States. [PDF]

BMC Health Serv Res
Chen F, Xu X, Wang X.
europepmc   +1 more source

Anti-TNF Therapies Promote a Proximal-to-Distal Healing Pattern in Moderate-to-Severe Ulcerative Colitis. [PDF]

Inflamm Bowel Dis
Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N.   +5 more
europepmc   +1 more source

Effect of tranexamic acid irrigation on perioperative blood loss during mini-percutaneous nephrolithotomy: A pilot double-blind randomised controlled trial. [PDF]

BJUI Compass
Prohsoontorn O, Sirisopana K, Piyawannarat S, Phengsalae Y, Sangkum P, Kongchareonsombat W, Ketsuwan C.   +6 more
europepmc   +1 more source